EMA Refused: Alpheon (recombinant human interferon alfa-2a) — BioPartners GmbH

View source ↗

Summary

The EMA refused approval for Alpheon (recombinant human interferon alfa-2a) from BioPartners GmbH for chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Alpheon (recombinant human interferon alfa-2a)

Snippet

Status: Refused. Therapeutic area: Hepatitis C, Chronic. MAH: BioPartners GmbH. Decision date: 28/06/2006